RSO 023
Alternative Names: RSO-023Latest Information Update: 07 Sep 2023
At a glance
- Originator RS Oncology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Sep 2023 Preclinical trials in Cancer in USA (unspecified route) (RS Oncology, September 2023)